PMID- 1431020
OWN - NLM
STAT- MEDLINE
DCOM- 19921223
LR  - 20221207
IS  - 0268-1315 (Print)
IS  - 0268-1315 (Linking)
VI  - 6 Suppl 5
DP  - 1992 Jun
TI  - New aspects in the treatment of depression.
PG  - 41-4
AB  - Because of the limitations in efficacy and safety of the older tricyclic 
      antidepressants (TCA) and monoamine oxidase inhibitors (MAOI) a number of new 
      approaches have been made in recent years to the treatment of depression to 
      obtain more effective, more rapidly acting, better tolerated and safer drugs. One 
      tactic has been to develop compounds with greater neuropharmacological 
      selectivity in inhibiting the neuronal reuptake of 5-HT. Most of these are as 
      effective as TCA but with fewer side-effects and greater safety. Another 
      development has been 'reversible' MAOI which reduce the risk of interaction with 
      tyramine-containing foods. For resistant depression the addition of lithium 
      (and/or tryptophan) may be effective, possibly through promoting 5-HT 
      neurotransmission. Continuous treatment with a selective 5-HT reuptake inhibitor 
      can reduce the relapse rate in patients with recurrent depression. Unfortunately, 
      these new approaches, despite their advantages in terms of side-effects and 
      safety, have thus far not proved to be more effective or faster acting than the 
      standard TCA. That remains a challenge for the future.
FAU - Silverstone, T
AU  - Silverstone T
AD  - Department of Psychological Medicine, Medical College, St Bartholomew's Hospital, 
      London, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int Clin Psychopharmacol
JT  - International clinical psychopharmacology
JID - 8609061
RN  - 0 (Monoamine Oxidase Inhibitors)
RN  - 0 (Serotonin Uptake Inhibitors)
SB  - IM
MH  - Depressive Disorder/*drug therapy/psychology
MH  - Humans
MH  - Long-Term Care
MH  - Monoamine Oxidase Inhibitors/adverse effects/*therapeutic use
MH  - Recurrence
MH  - Selective Serotonin Reuptake Inhibitors/adverse effects/*therapeutic use
EDAT- 1992/06/01 00:00
MHDA- 1992/06/01 00:01
CRDT- 1992/06/01 00:00
PHST- 1992/06/01 00:00 [pubmed]
PHST- 1992/06/01 00:01 [medline]
PHST- 1992/06/01 00:00 [entrez]
AID - 10.1097/00004850-199206005-00004 [doi]
PST - ppublish
SO  - Int Clin Psychopharmacol. 1992 Jun;6 Suppl 5:41-4. doi: 
      10.1097/00004850-199206005-00004.